Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting

Figures & data

Figure 1 Results: immunological (A) and virological (B) trends during follow-up according to single- or multi-tablet antiretroviral regimens.

Abbreviations: CD4, cluster of differentiation 4; MTR, multi-tablet regimen; STR, single-tablet regimen.

Table 1 Baseline characteristics of the 474 antiretroviral-naïve HIV-1 infected patients

Characteristic*	Overall (N=474)	STR (N=115)	MTR (N=359)	P-value (STR versus MTR)
Age, years	42.2 (9.5)	41.8 (9.6)	42.3 (9.5)	0.514
Sex, n (%)
Male	425 (90%)	108 (94%)	317 (88%)	0.112
Female	49 (10%)	7 (6%)	42 (12%)
Risk factor for HIV, n (%)
MSM	236 (50%)	48 (42%)	188 (52%)	<0.0001
IVDU	21 (4%)	2 (2%)	19 (5%)
Heterosexual	68 (14%)	8 (7%)	60 (17%)
Other/unknown	149 (32%)	57 (50%)	92 (26%)
Anti-HCV Ab, n (%)
Negative	374 (79%)	96 (84%)	278 (77%)	0.126
Positive	43 (9%)	5 (4%)	38 (11%)	0.040
Unknown	57 (12%)	14 (12%)	43 (12%)
Baseline CD4+ count, cells/μL	310 (163)	351 (175)	297 (156)	0.004
≤200	108 (23%)	19 (17%)	89 (25%)	0.068
201–350	193 (41%)	44 (38%)	149 (42%)
351–500	119 (25%)	33 (29%)	86 (24%)
>500	54 (11%)	19 (17%)	35 (10%)
Baseline HIV-RNA (log10 copies/mL)	4.50 (0.88)	4.36 (0.94)	4.55 (0.86)	0.068

Note:

* Described as mean (standard deviation) or frequency (%).

Abbreviations: Anti-HCV Ab, antibodies anti-HCV; CD4+, cluster of differentiation 4; IVDU, intravenous drug users; MSM, men who have sex with men; MTR, multi-tablet regimen; STR, single-tablet regimen.

Figure 2 Results: mean year cost per patient for STR versus MTR (in Euros).

Abbreviations: HAART, highly active antiretroviral therapy; MTR, multi-tablet regimen; STR, single-tablet regimen.

Table 2 Multivariate analysis (generalized linear model): factors associated with the overall cost (costs include antiretroviral regimens and hospitalizations and non-antiretroviral treatments)

Characteristics	Patients who did not switch during follow-up: persistence =100% (N=309)		Patients who switched during follow-up: persistence <100% (N=165)		All patients
	Adjusted* mean cost (SE), euros	P-value	Adjusted* mean cost (SE), euros	P-value	Adjusted* mean cost (SE), euros	P-value
CD4+, cells/μL
≤200	15,600 (1,377)	0.0034	20,260 (3,196)	0.095	17,232 (1,407)	0.0008
201–350	11,594 (1,231)		15,665 (3,357)		12,832 (1,320)
351–500	12,365 (1,365)		12,564 (3,196)		12,416 (1,388)
>500	13,059 (1,708)		14,607 (3,867)		13,924 (1,735)
First-line regimen
STR	11,161 (1,353)	<0.0001	13,973 (3,851)	0.261	12,096 (1,440)	0.0001
MTR	15,148 (1,186)		17,575 (2,455)		16,106 (1,174)

Note:

* Adjusted for age, sex, anti-HCV Ab, HIV risk factor, baseline HIV-RNA.

Abbreviations: CD4, cluster of differentiation 4; MTR, multi-tablet regimen; SE, standard error; STR, single-tablet regimen; anti-HCV Ab, antibodies anti-HCV.